Stay updated with breaking news from Effector Cell Therapy Program. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Drs Lunning and Jacobson discuss the characteristics of follicular lymphoma that may prompt aggressive treatment, the potential optimal role of CAR T-cell therapy in the third line and beyond, and how the toxicity profiles of different CAR T-cell products compare with each other.
Patient preferences should be considered when selecting the optimal treatment regimen for patients with relapsed/refractory follicular lymphoma, as both CD19-directed CAR T-cell therapies and CD20-targeted bispecific antibodies can be efficacious in this population, according to a presentation by Caron A. Jacobson, MD, MMSc, at the 2023 SOHO Annual Meeting.
Key opinion leaders discuss barriers to care for using CAR T-cell therapy for patients with large B-cell lymphoma, including time delays and lack of support for patients.
Treatment uses modified white blood cells to target cancer cells that are resistant to standard therapies.
94% of Patients Achieved a Response at 18 Months in Pivotal ZUMA-5 Trial -- -- Yescarta Reduced Risk of Death by 58% Compared to Current Therapies in Weighted Analysis of ZUMA-5 Compared to SCHOLAR-5 External Control Cohort -- -- Late-breaking Data Presented at European Hematology Association 2021 -- Kite, a Gilead Company today announced follow-up results from the pivotal ZUMA-5 trial of Yescarta ® the first and ...